Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Chinese Patients with R/R CD30+ HL or sALCL
NCT02939014Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), Anaplastic Large Cell Lymphoma (ALCL), sponsored by Takeda. Started Nov 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)Anaplastic Large Cell Lymphoma (ALCL)
Beyond the preview
Go deeper on NCT02939014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939014.